Impact of lipopolysaccharide-induced inflammation on the disposition of the aminocephalosporin cefadroxil

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6171-6178

  Huh, Yeamin ^a   Keep, Richard F ^b   Smith, David E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; CEFADROXIL; INTERLEUKIN 1BETA; INTERLEUKIN 6; INULIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 4; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PEPTIDE TRANSPORTER 2; PROBENECID; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; ABCC4 PROTEIN, MOUSE; ANTIINFECTIVE AGENT; CARRIER PROTEIN; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; PEPTIDE PERMEASE; PHARMACEUTICAL VEHICLES AND ADDITIVES; SLC22A6 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID LEVEL; CHOROID PLEXUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG CLEARANCE; DRUG DISPOSITION; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; INFLAMMATION; KIDNEY CLEARANCE; KIDNEY DYSFUNCTION; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE EXCRETION; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; URINALYSIS; URINARY EXCRETION; ANIMAL; BLOOD; CEREBROSPINAL FLUID; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; KIDNEY; METABOLISM; PATHOPHYSIOLOGY; URINE;

ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CEFADROXIL; GENE EXPRESSION; GLOMERULAR FILTRATION RATE; INFLAMMATION; KIDNEY; LIPOPOLYSACCHARIDES; MEMBRANE TRANSPORT PROTEINS; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PROBENECID;

EID: 84887456722     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01497-13     Document Type: Article

References (53)

1. Cressman AM, Petrovic V, Piquette-Miller M. 2012. Inflammationmediated changes in drug transporter expression/activity: implications for therapeutic drug response. Expert Rev. Clin. Pharmacol. 5:69-89.
2. Ruot B, Béchereau F, Bayle G, Breuillé D, Obled C. 2002. The response of liver albumin synthesis to infection in rats varies with the phase of the inflammatory process. Clin. Sci. (Lond.) 102:107-114.
3. Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH. 1987. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J. Clin. Invest. 79:1635-1641.
4. Don BR, Kaysen G. 2004. Serum albumin: relationship to inflammation and nutrition. Semin. Dial. 17:432-437.
5. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ. 2008. Regulation of drugmetabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab. Dispos. 36:205-216.
6. Morgan ET. 2009. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin. Pharmacol. Ther. 85:434-438.
7. Höcherl K, Schmidt C, Bucher M. 2009. COX-2 inhibition attenuates endotoxin-induced downregulation of organic anion transporters in the rat renal cortex. Kidney Int. 75:373-380.
8. Thadhani R, Pascual M, Bonventre JV. 1996. Acute renal failure. N. Engl. J. Med. 334:1448-1460.
9. Levy EM, Viscoli CM, Horwitz RI. 1996. The effect of acute renal failure on mortality. A cohort analysis. JAMA 275:1489-1494.
10. De Paepe P, Belpaire FM, Buylaert WA. 2002. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin. Pharmacokinet. 41:1135-1151.
11. Quintiliani R. 1982. A review of the penetration of cefadroxil into human tissue. J. Antimicrob. Chemother. 10(Suppl B):33-38.
12. Tanrisever B, Santella PJ. 1986. Cefadroxil. A review of its antibacterial, pharmacokinetic and therapeutic properties in comparison with cephalexin and cephradine. Drugs 32(Suppl 3):1-16.
13. Quintiliani R. 1986. Efficacy of a twice-daily regimen of cefadroxil in the treatment of respiratory tract infections. Drugs 32(Suppl 3):43-49.
14. Nightingale C. 1980. Pharmacokinetics of the oral cephalosporins in adults. J. Int. Med. Res. 8:2-8.
15. Leroy A, Humbert G, Godin M, Fillastre JP. 1982. Pharmacokinetics of cefadroxil in patients with impaired renal function. J. Antimicrob. Chemother. 10(Suppl B):39-46.
16. Khamdang S, Takeda M, Babu E, Noshiro R, Onozato ML, Tojo A, Enomoto A, Huang XL, Narikawa S, Anzai N, Piyachaturawat P, Endou H. 2003. Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Eur. J. Pharmacol. 465:1-7.
17. Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH. 1995. Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. J. Biol. Chem. 270:25672- 25677.
18. Wang W, Zolty E, Falk S, Summer S, Zhou Z, Gengaro P, Faubel S, Alp N, Channon K, Schrier R. 2008. Endotoxemia-related acute kidney injury in transgenic mice with endothelial overexpression of GTP cyclohydrolase. Am. J. Physiol. Renal Physiol. 294:F571-F576.
19. Schmidt C, Höcherl K, Schweda F, Kurtz A, Bucher M. 2007. Regulation of renal sodium transporters during severe inflammation. J. Am. Soc. Nephrol. 18:1072-1083.
20. Wang W, Jittikanont S, Falk SA, Li P, Feng L, Gengaro PE, Poole BD, Bowler RP, Day BJ, Crapo JD, Schrier RW. 2003. Interaction among nitric oxide, reactive oxygen species, and antioxidants during endotoxemia- related acute renal failure. Am. J. Physiol. Renal Physiol. 284:F532- F537.
21. Wang W, Li C, Summer SN, Falk S, Ljubanovic D, Schrier RW. 2008. Role of AQP1 in endotoxemia-induced acute kidney injury. Am. J. Physiol. Renal Physiol. 294:F1473-1480.
22. Marques F, Sousa JC, Coppola G, Falcao AM, Rodrigues AJ, Geschwind DH, Sousa N, Correia-Neves M, Palha JA. 2009. Kinetic profile of the transcriptome changes induced in the choroid plexus by peripheral inflammation. J. Cereb. Blood Flow Metab. 29:921-932.
23. Keep RF, Si X, Shakui P, Ennis SR, Betz AL. 1999. Effect of amiloride analogs on DOCA-salt-induced hypertension in rats. Am. J. Physiol. 276: H2215-H2220.
24. Schmittgen TD, Livak KJ. 2008. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3:1101-1108.
25. Shen H, Ocheltree SM, Hu Y, Keep RF, Smith DE. 2007. Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. Drug Metab. Dispos. 35: 1209-1216.
26. Bins JW, Mattie H. 1988. Saturation of the tubular excretion of betalactam antibiotics. Br. J. Clin. Pharmacol. 25:41-50.
27. García-Carbonell MC, Granero L, Torres-Molina F, Aristorena JC, Chesa-Jimenez J, Pla-Delfina JM, Peris-Ribera JE. 1993. Nonlinear pharmacokinetics of cefadroxil in the rat. Drug Metab. Dispos. 21:215-217.
28. Ocheltree SM, Shen H, Hu Y, Keep RF, Smith DE. 2005. Role and relevance of peptide transporter 2 (PEPT2) in the kidney and choroid plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2 knockout mice. J. Pharmacol. Exp. Ther. 315:240-247.
29. Gabay C, Kushner I. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340:448-454.
30. Ho EA, Piquette-Miller M. 2007. KLF6 and HSF4 transcriptionally regulate multidrug resistance transporters during inflammation. Biochem. Biophys. Res. Commun. 353:679-685.
31. Sukhai M, Yong A, Kalitsky J, Piquette-Miller M. 2000. Inflammation and interleukin-6 mediate reductions in the hepatic expression and transcription of the mdr1a and mdr1b genes. Mol. Cell Biol. Res. Commun. 4:248-256.
32. Takeda M, Babu E, Narikawa S, Endou H. 2002. Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur. J. Pharmacol. 438:137-142.
33. de Waart DR, van de Wetering K, Kunne C, Duijst S, Paulusma CC, Oude Elferink RP. 2012. Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab. Dispos. 40:515-521.
34. Pentel P, Benowitz N. 1984. Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies. Clin. Pharmacokinet. 9:273-308.
35. Wang W, Falk SA, Jittikanont S, Gengaro PE, Edelstein CL, Schrier RW. 2002. Protective effect of renal denervation on normotensive endotoxemia- induced acute renal failure in mice. Am. J. Physiol. Renal Physiol. 283:F583-587.
36. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095.
37. Rodríguez CA, Smith DE. 1992. Influence of angiotensin II-induced alterations in renal flow on excretion of cefonicid in isolated perfused rat kidneys. Antimicrob. Agents Chemother. 36:616-619.
38. Hinshaw LB. 1996. Sepsis/septic shock: participation of the microcirculation: an abbreviated review. Crit. Care Med. 24:1072-1078.
39. Ljubojević M, Balen D, Breljak D, Kusan M, Anzai N, Bahn A, Burckhardt G, Sabolić I. 2007. Renal expression of organic anion transporter OAT2 in rats and mice is regulated by sex hormones. Am. J. Physiol. Renal Physiol. 292:F361-F372.
40. Shen H, Keep RF, Hu Y, Smith DE. 2005. PEPT2 (Slc15a2)-mediated unidirectional transport of cefadroxil from cerebrospinal fluid into choroid plexus. J. Pharmacol. Exp. Ther. 315:1101-1108.
41. Silver IA. 1977. Tissue pO2 changes in acute inflammation. Adv. Exp. Med. Biol. 94:769-774.
42. Sawyer RG, Spengler MD, Adams RB, Pruett TL. 1991. The peritoneal environment during infection. The effect of monomicrobial and polymicrobial bacteria on pO2 and pH. Ann. Surg. 213:253-260.
43. Swallow CJ, Grinstein S, Rotstein OD. 1992. Lipopolysaccharide impairs macrophage cytoplasmic pH regulation under conditions simulating the inflammatory microenvironment. J. Leukoc. Biol. 52:395-399.
44. Piquette-Miller M, Pak A, Kim H, Anari R, Shahzamani A. 1998. Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm. Res. 15:706-711.
45. Hartmann G, Kim H, Piquette-Miller M. 2001. Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int. Immunopharmacol. 1:189-199.
46. Hartmann G, Cheung AK, Piquette-Miller M. 2002. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J. Pharmacol. Exp. Ther. 303:273-281.
47. Bochud PY, Calandra T. 2003. Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 326:262-266.
48. Glauser MP, Zanetti G, Baumgartner JD, Cohen J. 1991. Septic shock: pathogenesis. Lancet 338:732-736.
49. Bone RC. 1991. The pathogenesis of sepsis. Ann. Intern. Med. 115:457- 469.
50. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T. 2001. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J. Antimicrob. Chemother. 47:421-429.
51. Lipman J, Wallis SC, Rickard CM, Fraenkel D. 2001. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med. 27:363-370.
52. Tang GJ, Tang JJ, Lin BS, Kong CW, Lee TY. 1999. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol. Scand. 43:726-730.
53. Takeda M, Tojo A, Sekine T, Hosoyamada M, Kanai Y, Endou H. 1999. Role of organic anion transporter 1 (OAT1) in cephaloridine (CER)- induced nephrotoxicity. Kidney Int. 56:2128-2136.